Mark J Enyedy insider trades

Open-market stock purchases and sales by Mark J Enyedy, Director at Biomarin Pharmaceutical Inc, from SEC Form 4 filings since Jun 6, 2014.

Recent trades

DateStockTradeValue
Jun 2, 2026BMRN Biomarin Pharmaceutical IncBought (not open market)—
May 8, 2026CRL Charles River Laboratories International, IncBought (not open market)$255K

Companies traded

  • BMRN Biomarin Pharmaceutical Inc: other filings, last Jun 2, 2026
  • CRL Charles River Laboratories International, Inc: other filings, last May 8, 2026
  • IMGN ImmunoGen, Inc: 1 buy, 7 sales, last Feb 12, 2024
  • LOGC LogicBio Therapeutics, Inc: other filings, last Nov 16, 2022
  • AKBA Akebia Therapeutics, Inc: other filings, last Jun 5, 2020
  • KERX Keryx Biopharmaceuticals Inc: other filings, last Dec 12, 2018
  • FATE Fate Therapeutics Inc: other filings, last May 2, 2017

Get free alerts when Mark J Enyedy files a new trade →